Market Update: Pfizer Inc (NYSE:PFE) – Pfizer’s Phase 2 Study Demonstrates Safety, Tolerability and Immunogenicity of TRUMENBA® When Coadministered with Meningococcal A, C, Y and W-135 Polysaccharide Conjugate (MCV4) and Tetanus, Diphtheria and Pertussis (Tdap) Vaccines in Adole

[Business Wire] – Pfizer Inc. announced today that researchers presented for the first time data from a randomized, controlled Phase 2 study of its meningococcal serogroup B vaccine, TRUMENBA®, coadministered with routine meningococcal . . . → Read More: Market Update: Pfizer Inc (NYSE:PFE) – Pfizer’s Phase 2 Study Demonstrates Safety, Tolerability and Immunogenicity of TRUMENBA® When Coadministered with Meningococcal A, C, Y and W-135 Polysaccharide Conjugate (MCV4) and Tetanus, Diphtheria and Pertussis (Tdap) Vaccines in Adole Similar Articles: Company Update (NYSE:PFE): Pfizer Begins Phase 2b Study Of Its Investigational Multi-antigen Staphylococcus aureus Vaccine In Adults Undergoing Elective Spinal Fusion Surgery Market Update: Pfizer Inc (NYSE:PFE) – U.S. CDC updates recommendation for new meningitis B vaccines Stock Update: Pfizer Inc (NYSE:PFE) – GSK sells two vaccines to Pfizer to ease competition concerns